

# Cost-Analysis of FreeStyle Libre Devices from the National Health System Perspective in Patients with T2D on Basal Insulin Treatment and Poor Glycemic Control in Spain

Gómez-Peralta, Fernando<sup>1</sup>; De la Cuadra-Grande, Alberto<sup>2</sup>; Mezquita-Raya, Pedro<sup>3</sup>; Hernández Martínez, Antonio-Miguel<sup>4</sup>; Cebrián-Cuenca, Ana María<sup>5</sup>; Carretero-Gómez, Juana<sup>6</sup>; Bellido-Castañeda, Virginia<sup>7</sup>; Ampudia-Blasco, Francisco Javier<sup>8</sup>

## INTRODUCTION

- FreeStyle Libre® systems (FSL) are effective<sup>1-4</sup> and produce cost-savings vs. self-monitoring blood glucose (SMBG) in type 1<sup>5</sup> and type 2 diabetes (T2D) on multiple doses of insulin (MDI)<sup>6</sup>.
- Data from RELIEF study suggest that FSL are also effective in patients with T2D receiving basal insulin<sup>4</sup>.

## OBJECTIVE

This cost-analysis evaluated the use of FSL versus SMBG in patients with T2D on basal insulin with poor glycemic control (HbA1c>8%) in Spain.

## METHODS

- A decision analytic model was designed to estimate costs derived from the consumption of glucose monitoring resources, acute diabetic events and chronic diabetic complications. Inputs were extracted from scientific literature and validated by national multidisciplinary experts.
- According to national guidelines<sup>7</sup>, a consumption of 2.5 strips/day (€0.55/unit, VAT included)<sup>8</sup> and 2,5 lancets/day (€0.14/unit, VAT included)<sup>8</sup> was considered for SMBG. FSL reduced the usage of strips/lancets by 83%<sup>4</sup>.
- An annual consumption of 26 sensors was considered (€3.00/day, VAT included).
- The annual frequency of diabetic complications is presented in Table 1. FSL was associated with a HbA1c decrease of 1.1%<sup>9</sup> (events with FSL were estimated by the reduction per 1% HbA1c).
- Sensitivity analyses (SA) were conducted to test model robustness: **1)** Unit cost of strips and lancets at €0.00; **2)** Frequency of SHEs: 1.4 events/person-year<sup>27</sup>; **3)** Decrease of HbA1c with FSL: 0.45%<sup>28</sup>.

**Table 1. Clinical inputs and related costs.**


	SMBG [↓ with FSL] <sup>4</sup>	Cost/event (€, 2024)
<b>MHE</b> (event/person-year) <sup>10</sup>	17.02 [58%]	€3.81 11,12
<b>SHE</b> (event/person-year) <sup>10</sup>	2.5 [58%]	€1,364 13-16
<b>DKA</b> (event/person-year) <sup>17</sup>	0.003 [68%]	€2,453 15,17
<b>Chronic events</b> (event/person-year) <sup>18</sup> [Frequency reduction per 1% decreased HbA1c]		
AMI	0.07 [14%] <sup>19</sup>	€1,214 <sup>8</sup>
Angina pectoris	0.09 [10%] <sup>20</sup>	€670 <sup>8,22</sup>
HF	0.06 [16%] <sup>19</sup>	€1,482 <sup>8,23</sup>
Stroke	0.04 [12%] <sup>19</sup>	€3,101 <sup>8,24</sup>
Transitory ischemia	0.04 [12%] <sup>19</sup>	€2,774 <sup>25</sup>
Neuropathy	0.05 [37%] <sup>19</sup>	€3,961 <sup>8,26</sup>
Retinopathy	0.08 [19%] <sup>19</sup>	€3,845 <sup>8</sup>
Peripheral angiopathy	0.05 [17%] <sup>21</sup>	€1,086 <sup>8</sup>
Nephropathy	0.09 [22%] <sup>19</sup>	€1,884 <sup>25</sup>
ESRD	0.06 [22%] <sup>19</sup>	€41,593 <sup>8</sup>

AMI: Acute Myocardial Infarction; DKA: Diabetic Ketoacidosis; ESRD: End-Stage Renal Disease; FSL: FreeStyle Libre® systems; HF: Heart Failure; MHE: Mild Hypoglycemic Event; SHE: Severe Hypoglycemic Event; SMBG: Self-Monitoring Blood Glucose.


## RESULTS

- In 1,000 patients FSL would prevent 11,323 acute events (Figure 1) and 124 chronic complications (Figure 2).

**Figure 1. Acute events (1,000 patients) \*.**



**Figure 2. Chronic complications (1,000 patients) \*.**



AMI: Acute Myocardial Infarction; DKA: Diabetic Ketoacidosis; ESRD: End-Stage Renal Disease; FSL: FreeStyle Libre® systems; HF: Heart Failure; SHE: Severe Hypoglycemic Event; SMBG: Self-Monitoring Blood Glucose. \* Time horizon: 1 year.

- The total annual cost per patient was €6,853.87 for SMBG and €5,075.58 for FSL. Thus, in 1,000 patients, FSL would reduce total annual costs by €1,778,289.
- Although FSL sensors increased costs by €1,096,794, cost-savings were observed in the consumption of strips and lancets (-€522,947), mild hypoglycemia (-€ 37,617), SHE (-€ 1,455,204), DKA (-€4,174) and chronic diabetic complications (-€855,141).
- All SAs confirmed cost-savings: **1)** -€1,255,342; **2)** -€1,137,999; **3)** -€1,272,978.

## CONCLUSION



Compared to SMBG, FSL by reducing acute and chronic complications in poorly controlled (HbA1c>8%) patients with T2D on basal insulin, lead to significant cost-savings from the Spanish Health System.

**Authors Filiations:** **1)** Hospital General de Segovia; **2)** Pharmacoeconomics & Outcomes Research Iberia (PORIB); **3)** Hospital Universitario de Torrecárdenas; **4)** Hospital Universitario Virgen de la Arrixaca; **5)** Centro de Salud de Cartagena Casco; **6)** Hospital Universitario de Badajoz; **7)** Hospital Universitario Virgen del Rocío; **8)** Hospital Clínico Universitario de Valencia, Medicine Faculty, University of Valencia.

**References:** **1)** Bolinder J. The Lancet. 2016;388(10057):2254–63; **2)** Nathanson D. Diabetologia. 2021;64(7):1595–603; **3)** Haak T. Diabetes Ther. 2017;8(1):55–73; **4)** Guerci B. Diabetes Technology & Therapeutics. 2023;25(1):20–30; **5)** Oyagüez I. BMJ Open Diabetes Res Care. 2020;8(1):e001330; **6)** Oyagüez I. Diabetes Ther. 2021;12(9):2329–42; **7)** Menéndez Torre E. Av En Diabetol. 2012;28:3-9; **8)** González Pacheco H. 2021. [https://sescs.es/wp-content/uploads/2022/07/SESCS\\_Informe-final-EM\\_FLASH\\_DEF\\_NIPO.pdf?x55084](https://sescs.es/wp-content/uploads/2022/07/SESCS_Informe-final-EM_FLASH_DEF_NIPO.pdf?x55084); **9)** Carlson AL. BMJ Open Diab Res Care. 2022;10(1):e002590; **10)** Khunti K. Diabetes Obes Metab. 2016;18:907-15; **11)** Orozco-Beltrán D. Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2014;5:155-68; **12)** Orozco-Beltrán D. Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2014;5:155-68; **13)** Ampudia-Blasco FJ. Endocrinol Diabetes Nutr. 2021;68:557-66; **14)** Crespo C. Av En Diabetol. 2013;29:182-9; **15)** Barranco RJ. Diabet Med J Br Diabet Assoc. 2015;32:1520-6; **16)** Hammer M. J Med Econ. 2009;12(4):281-90; **17)** Barranco RJ. Diabet Med J Br Diabet Assoc. 2017;34:966-72; **18)** Arrieta F. Avances en Diabetología. 2011;27(2):53-60; **19)** Stratton IM. BMJ. 2000;321(7258):405-12; **20)** Eeg-Olofsson K. J Intern Med. 2010;268(5):471-82; **21)** Zhou ZY. Int J Low Extrem Wounds. 2015;14(2):168-77; **22)** Schwander B. Value Health. 2009;12(6):857-71; **23)** Delgado JF. Rev Esp Card. 2014;67(8):643-50; **24)** López-Bastida J. BMC Health Serv Res. 2012;12(1):315; **25)** Spanish Health Ministry. 2024. <https://pestadistico.inteligenciadegestion.sanidad.gob.es/publicoSNS/N/rae-cmbd/rae-cmbd>; **26)** Ray JA. Curr Med Res Op. 2005;21(19):1617-29; **27)** ChantzarasA. Patient-Reported Outcomes. 2022;30:9-17; **28)** Evans M. Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2022;13(6):1175-85.